Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

188 results about "Proteolysis targeting chimera" patented technology

A proteolysis targeting chimera (PROTAC) is a heterofunctional small molecule composed of two active domains and a linker capable of removing specific unwanted proteins. Rather than acting as a conventional enzyme inhibitor, a PROTAC works by inducing selective intracellular proteolysis. PROTACs consist of two covalently linked protein-binding molecules: one capable of engaging an E3 ubiquitin ligase, and another that binds to a target protein meant for degradation. Recruitment of the E3 ligase to the target protein results in ubiquitination and subsequent degradation of the target protein by the proteasome. Because PROTACs need only to bind their targets with high selectivity (rather than inhibit the target protein's enzymatic activity), there are currently many efforts to retool previously ineffective inhibitor molecules as PROTACs for next-generation drugs.

KRAS proteolysis targeting chimeras

Provided herein are KRAS proteolysis targeting chimeras (PROTACs), compositions comprising the KRAS PROTACs, and methods of making and using the KRAS PROTACs, e.g., to promote degradation of KRAS and / or treat KRAS-associated cancers. In an embodiment, the KRAS PROTAC has the following structural formula: or a pharmaceutically acceptable salt thereof, wherein values for the variables (e.g., Ring A, X4, Y, R2, R3, R4, L', Degron) are as described herein.
Owner:PAQ THERAPEUTICS INC

KRAS proteolysis targeting chimeras

Provided herein are KRAS proteolysis targeting chimeras (PROTACs), compositions comprising the KRAS PROTACs, and methods of making and using the KRAS PROTACs, e.g., to promote degradation of KRAS and / or treat KRAS-associated cancers. In an embodiment, the KRAS PROTAC has the structural formula (I) or a pharmaceutically acceptable salt thereof, wherein values for the variables are as described herein.
Owner:PAQ THERAPEUTICS INC

Protac compounds binding KEAP1 ubiquitin ligase for targeted protein degradation

The present disclosure relates to methods of co-administering PROTAC (proteolysis targeting chimera) compounds that can promote ubiquitination and degradation of a target protein. The present disclosure also relates to antibody drug conjugates of PROTAC compounds Also disclosed herein are pharmaceutical compositions that can include a compound of Formula (V), the use and preparation thereof.
Owner:SEED THERAPEUTICS US INC +1

Cerebellar protein e3 ubiquitin ligase inhibitor and chimeric compound targeting protein degradation

PCT designated stage expiredWO2024240268A1Organic active ingredientsOrganic chemistryProtein targetUbiquitin Ligase Inhibitors
The present invention provides a novel human cerebellar protein (CRBN) E3 ubiquitin ligase inhibitor, capable of being used to prepare a PROTAC molecule. The CRBNE3 ubiquitin ligase inhibitor and the PROTAC molecule can be used to treat cancer and other diseases.
Owner:GAN & LEE PHARM CO LTD

Targeting chimera based on cationic polymer protein hydrolysis as well as preparation and application of targeting chimera

The invention discloses a cationic polymer-based proteolysis targeting chimera as well as preparation and application thereof, and belongs to the fields of targeting protein degradation and nanotechnology. According to the chimera, a cationic polymer is used as a connecting arm to connect a target protein ligand and an E3 ubiquitin ligase ligand to form a ternary complex, so that efficient degradation of target protein is realized. By adjusting the ligand proportion, chimeras with different degradation efficiencies can be synthesized, and accurate regulation and control are realized. The pH-responsive nano-drug obtained by hydrolyzing the targeting chimera by using the targeting protein can respond to an acidic tumor microenvironment, specifically release the chimera, and improve the targeting property and the treatment effect of the drug. Compared with the traditional PROTACs, the compound has higher bioavailability and tumor permeation effect; the preparation method of the nano-drug is simple and easy to implement, provides possibility for preparation of high-performance nano-drugs, shows potential in preparation of anti-tumor cell drugs, provides new thoughts and methods for tumor treatment, and has important clinical application value.
Owner:SHAANXI UNIV OF SCI & TECH

Celastrol proteolysis targeting chimeras

The present application provides compounds that are proteolysis targeting chimeras containing a celastrol-based ubiquitin ligase targeting moiety. Methods of using these compounds for treating various diseases, such as neurodegenerative diseases and cancer, are also provided.
Owner:THE GENERAL HOSPITAL CORP +1

Cyanoquinoline-targeting protein degradation molecule, preparation method therefor and use thereof

PCT designated stage expiredWO2025011623A1Organic chemistryAntineoplastic agentsDiseaseProtein target
Provided are a cyanoquinoline-targeting protein degradation molecule, a preparation method therefor and a use thereof. Particularly, the present invention relates to a compound represented by general formula (I), a preparation method therefor, a pharmaceutical composition comprising the compound, and a use of the compound as a protein degradation targeting chimera of an androgen receptor in preparation of medicaments for treating related diseases (including prostate cancer, breast cancer, and spinal and bulbar muscular atrophy) controlled by the androgen receptor, wherein the definitions of the substituents in general formula (I) are the same as those in the description.
Owner:SHANGHAI YIDI BIOTECHNOLOGY CO LTD

Programmable DNA proteolytic target chimeras and methods of use thereof

Described herein are programmable DNA proteolytic target chimera complexes that can be used both for the direct treatment of cancer by inhibiting biochemical pathways that are overexpressed in cancer cells, and for the indirect treatment of cancer by recruiting the E3 ligase complex to engage with a protein of interest or a mutant thereof and initiating proteolysis. Also described herein are methods of using the complexes in the treatment of cancer, as well as compositions comprising the complexes.
Owner:THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIV OF ARIZONA

Protein degradation targeting chimera and application thereof

The invention belongs to the technical field of medicines, and particularly relates to a protein degradation targeting chimera and application thereof. The protein degradation targeting chimera has a structure as shown in a formula (I), and the definition of each group in the formula is shown in the specification. The compound shown in the formula (I) has better inhibitory activity on CDK2. # imgabs0 #
Owner:SMASHBIO (BEIJING) THERAPEUTICS CO LTD

IDO1-targeting polypeptide and IDO1 protein degradation targeting chimera

The invention belongs to the technical field of biological medicines, and particularly relates to a polypeptide targeting IDO1 and an IDO1 protein degradation targeting chimera. The IDO1 targeting polypeptide provided by the invention is an IDO1 extracellular domain protein binding polypeptide with high affinity and targeting property, which is obtained through successful panning by adopting a phage display technology. The polypeptide has strong binding force with IDO1 extracellular domain structural protein, and has the characteristics of high sensitivity, high recognition efficiency and small molecular weight. The polypeptide and E3 ubiquitin ligase ligand thalidomide are further reasonably designed to obtain PROTAC, and the PROTAC has good endocytosis capacity and IDO1 targeted degradation capacity, so that treatment drugs for cancer diseases have higher selectivity, and higher treatment efficiency is provided while systemic toxicity is reduced. Therefore, a brand new treatment strategy and effective technical support can be provided for research and development of novel tumor targeting drugs and treatment of related cancers.
Owner:ZHENGZHOU UNIV

Structural analysis system and modeling method for protein degradation targeted chimera complexes

The invention discloses a structural analysis system and a modeling method for a protein degradation targeting chimera compound, and belongs to the field of computer-aided drug molecule design. The structural analysis system comprises a chimera component analysis module, a chimera induced complex component analysis module and a chimera linker length distribution analysis module, so that automatic structural splitting and analysis of the protein degradation targeted chimera drug are realized; through protein-protein docking, conformation search, conformation fusion and optimization, conformation clustering and conformation scoring and sorting, efficient and accurate structure modeling is realized. According to the method, automatic component splitting and structure analysis can be carried out, so that a potential drug molecule binding mode is comprehensively explored, the trial and error cost and time of traditional drug structure analysis are remarkably reduced, the design efficiency and success rate of a protein degradation targeting chimera are remarkably improved, and through automatic parameter optimization, the design efficiency of the protein degradation targeting chimera is greatly improved. And the high efficiency and reliability of the structure modeling process are ensured.
Owner:ZHEJIANG UNIV

Novel HIF-2alpha protein hydrolysis degradation agent as well as preparation method and application thereof

The invention discloses a novel HIF-2 alpha proteolysis targeting chimera 1 as well as a preparation method and application thereof, the structural formula 1 of the novel HIF-2 alpha proteolysis targeting chimera 1 is shown in the specification, and the obtained novel HIF-2 alpha proteolysis targeting chimera 1 has good proliferation inhibition activity on kidney cancer 786-O cells. The novel HIF-2alpha protein hydrolysis targeting chimera designed by the invention is novel in structure, few in preparation route process steps, easy to obtain raw materials, suitable for industrial production and good in application value.
Owner:ZIBO RUIGUANGZHENGXIN BIOLOGICAL TECH CO LTD

Preparation method and application of targeted protein degradation nanoparticles wrapped by liposome vesicles

The invention discloses a preparation method and application of targeted protein degradation nanoparticles wrapped by liposome vesicles. The preparation method comprises the following steps: blending a protein degradation targeting chimera based on polydimethyldiguanide with hyaluronic acid, and forming polyprotein degradation targeting chimera nanoparticles through an electrostatic adsorption effect; and blending the liposome vesicles with the polyprotein degradation targeting chimera nanoparticles, and carrying out co-extrusion to obtain the targeting protein degradation nanoparticles wrapped by the liposome vesicles. The targeting protein degradation nano-particles wrapped by the liposome vesicles can overcome the hook effect of the protein degradation targeting chimera in tumor cells and achieve long circulation of the protein degradation targeting chimera in a living body, the in-vivo utilization rate of the protein degradation targeting chimera can be increased to the maximum extent, and the anti-tumor effect is enhanced.
Owner:UNIV OF SCI & TECH OF CHINA

Protein degradation targeting chimera based on G-quadruplex RNA as well as preparation method and application thereof

The invention provides a protein degradation targeting chimera based on G-quadruplex RNA (Ribonucleic Acid) as well as a preparation method and application of the protein degradation targeting chimera. The structural general formula of the protein degradation targeting chimera is G-L-E, wherein G is G quadruplex RNA specifically combined with mammal fragile X hypophrenia protein (FMRP), E is a ligand of micromolecule E3 ubiquitination ligase, and L is a connecting arm between the G quadruplex RNA and the ligand of the micromolecule E3 ubiquitination ligase. The protein degradation targeting chimera provided by the invention has the advantages that the stability in an in-vivo environment and the capability of entering cells are greatly improved, and the protein degradation targeting chimera also has the capabilities of efficiently degrading FMRP and changing a secretion mode of cancer cells, so that a lot of convenience is provided for the development of nucleic acid PROTAC drugs.
Owner:HUNAN UNIV

DNA-based proteolysis targeting chimera (SDTAC) and methods of their use for treating diseases

Described herein are nucleic acid complexes which act as spatially activatable PROTACS which can be configured to optimally target a protein of interest with an E3 ligase. The nucleic acid complexes involve double-stranded DNA, XNAs, DNA / RNA hybrids, and double-stranded RNA.
Owner:THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIV OF ARIZONA

Protein degradation targeting chimera molecule and application thereof

The invention provides a protein degradation targeting chimera molecule and application thereof, the protein degradation targeting chimera molecule has a structure as shown in a formula (I), the protein degradation targeting chimera molecule can significantly degrade IRAK kinase, shows an efficient and high-selectivity IRAK4 and / or IRAK1 degradation effect, and can be used for preparing an IRAK kinase inhibitor. The compound can be used for treating or preventing diseases related to the activity of IRAK4 and / or IRAK1.
Owner:KEHUI ZHIYAO BIOTECHNOLOGY (SHENZHEN) CO LTD

GPER proteolytic targeting chimeras

To provide PROteolytic TArgeting Chimeras (PROTACs) capable of inactivating a G-protein coupled estrogen receptor (GPER).SOLUTION: A molecule comprising a G-protein coupled estrogen receptor (GPER) ligand coupled to a linker coupled to an E3 ubiquitin ligase ligand and methods of using the molecule are provided. In one embodiment, the GPER ligand is estradiol and the E3 ubiquitin ligase ligand is (S,R,S)-AHPC.SELECTED DRAWING: Figure 1
Owner:THE UNIVERSITY OF IOWA RESEARCH

Proteolysis targeting chimera compound for degrading IRAK4 and use thereof

The present application relates to a proteolysis targeting chimera compound represented by formula (A) for degrading IRAK4 and a preparation method therefor, a pharmaceutical composition comprising said compound, and a use of the pharmaceutical composition for treating diseases, disorders or conditions associated with the kinase protein IRAK4.
Owner:SHENZHEN ZHONGGE BIOLOGICAL TECH CO LTD

Protein degradation targeting chimera and application thereof

The invention belongs to the field of pharmacy, and relates to a protein degradation targeting chimera (PROTAC) taking PD-L1 as a target spot and medical application thereof. The protein degradation targeting chimera is a compound composed of a target protein ligand, an E3 ligase ligand and a linker and a pharmaceutically acceptable salt of the compound, the specific structure of the compound is as shown in a formula I, and substituent groups are described in the specification in detail. A Western blot experiment (Western Blot) shows that the compound disclosed by the invention can be used for degrading the protein PD-L1 in a targeted manner.
Owner:SHENYANG PHARMA UNIV

Model training method and apparatus, and molecular structure information recommendation method and apparatus

PCT designated stage expiredWO2024234749A1BiostatisticsBiological modelsData setData mining
Disclosed are a model training method and apparatus, a molecular structure information recommendation method and apparatus, a storage medium, and an electronic device. The model training method comprises: acquiring a proteolysis targeting chimera data set; according to the proteolysis targeting chimera data set, constructing three-dimensional molecular graph information of a designated proteolysis targeting chimera; inputting the three-dimensional molecular graph information of the designated proteolysis targeting chimera into a prediction model to be trained, to obtain fragment information of a molecular fragment combining with the designated proteolysis targeting chimera to have a preset medical function, and using the fragment information of the combined molecular fragment as target fragment information; training the prediction model according to deviations between multiple pieces of predicted target fragment information and fragment information of labelled molecular fragments corresponding to multiple specified proteolysis targeting chimeras.
Owner:ZHEJIANG LAB

Proteolysis targeting chimera as well as preparation method, pharmaceutical composition and application thereof

The invention belongs to the technical field of chemical medicine synthesis, and particularly relates to a proteolysis targeting chimera as well as a preparation method, a pharmaceutical composition and application thereof. The structural formula of the proteolysis targeting chimera is shown as a formula Ia or a formula Ib; the preparation process is simple and easy to implement, and the prepared proteolysis targeted chimera or the pharmaceutically acceptable salt thereof has the effect of efficiently degrading CDK2 / 4 / 6 / 9 in a targeted manner and has relatively high selectivity; experimental results show that the compound can utilize a ubiquitin-proteasome system to induce targeted degradation of CDK2 / 4 / 6 / 9 protein and inhibit downstream signal channels of the protein, selective degradation of the CDK2 / 4 / 6 / 9 is achieved on the protein level, the cell level and the animal level, and the compound has a good effect of resisting prostate cancer cell proliferation. # imgabs0 #
Owner:HEBEI KANGTAI PHARMA

Degradation agent based on benzimidazole fused covalent warhead as well as preparation method and application of degradation agent

The invention discloses a degradation agent based on benzimidazole fused covalent warheads as well as a preparation method and application of the degradation agent, and relates to the technical field of drug development. The structural formula of the degradation agent based on the benzimidazole fused covalent warhead is shown in the specification, wherein, is phenyl or substituted phenyl; r is methyl or tertiary butyl; the structure is selected from one of the following structures:,,,,,,,,, and; and a connection site is represented. According to the invention, a series of degradation agents based on benzimidazole fused covalent warheads are obtained by utilizing the modular design of a benzimidazole guiding group and an acrylate covalent warhead and then connecting with a BRD4 protein inhibitor JQ1 through a connexon. The degradation agent based on the benzimidazole fused covalent warhead can target the BRD4 protein and efficiently degrade the BRD4 protein. Therefore, targeted degradation of the BRD4 protein is realized while a protein degradation targeted chimera molecular library is enriched.
Owner:SHENZHEN UNIV

Bifunctional chimera heterocyclic compound for targeted degradation of androgen receptor and application of bifunctional chimera heterocyclic compound

The invention relates to a difunctional chimera heterocyclic compound for targeted degradation of an androgen receptor and application of the difunctional chimera heterocyclic compound, and particularly provides a compound shown in a formula (I), or an isotope compound of the compound, or an optical isomer of the compound, or a tautomer of the compound, or a pharmaceutically acceptable salt of the compound, or a prodrug of the compound, or a solvate of the compound, aRB is an androgen receptor recognition / combination part, L is a linking part, and U is a ubiquitin protease recognition / combination part; the three parts are connected through chemical bonds. The compound provided by the invention can degrade androgen receptors in prostate cancer cells in a targeted manner and inhibit proliferation of the prostate cancer cells, and also shows good metabolic stability and pharmacokinetic properties. The compound provided by the invention has a good application prospect in preparation of a protein degradation targeting chimera of an androgen receptor and in preparation of drugs for treating related diseases (including prostatic cancer, breast cancer and Kenildie disease) regulated and controlled by the androgen receptor. # imgabs0 #
Owner:HINOVA PHARM INC

Proteolysis targeting chimera and preparation method thereof

The invention discloses a proteolysis targeting chimera and a preparation method thereof, and relates to the technical field of medicine preparation, the key points of the technical scheme are as follows: the proteolysis targeting chimera comprises RD1, RD2, RD3, RD4, RD5, RD6, RD7, RD8, RD9, RD10, RD11, RD12, RD13 and RD14, and the structure of the proteolysis targeting chimera is composed of a general structure (warhead R1 of RNF4), a VHL ligand or CRBN ligand and a linker; the structure of warhead R1 of RNF4 is as follows: # imgabs0 #, the structure of VHL ligand is as follows: # imgabs1 #, and the structure of CRBN ligand is as follows: # imgabs2 #
Owner:WUHAN HONGREN BIOPHARMACEUTICAL INC

A drug delivery system of ultrasound-enhanced synergistic immunity and a preparation method and application thereof

PendingCN122163546ADigestive systemPharmaceutical delivery mechanismCancer cellPhospholipid formation
This invention relates to the field of nanomedicine delivery systems, specifically to an ultrasound-enhanced synergistic immunotherapy drug delivery system, its preparation method, and its applications. The ultrasound-enhanced synergistic immunotherapy drug delivery system includes a lipid shell and a fluorocarbon gas encapsulated within the lipid shell. The lipid shell is made from cancer cell membranes and a lipid membrane formed from synthetic phospholipids. The lipid shell integrates a protein degradation-targeting chimera for degrading PD-L1. This invention combines targeted drug delivery, PD-L1 targeted degradation, and ultrasound enhancement technology to construct an integrated synergistic immunotherapy drug delivery system. Through multi-mechanism synergistic action, it overcomes the bottlenecks of existing PROTAC delivery systems, achieving a highly efficient anti-tumor immune response. This technical solution solves the technical problems of limited tumor tissue penetration and cellular uptake efficiency of PROTAC degrading agents targeting PD-L1, resulting in unsatisfactory delivery effects and promising prospects for widespread application.
Owner:THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY

Bi-functional compounds and methods for targeted ubiquitination of androgen receptor

The present invention relates to bi-functional compounds which function to recruit endogenous proteins to an E3 ubiquitin ligase for degradation, and methods for using same. More specifically, the present disclosure provides specific proteolysis targeting chimera (PROTAC) molecules which find utility as modulators of targeted ubiquitination of a variety of polypeptides and other proteins, in particular the androgen receptor of a slice variant of AR which lacks the LBD, labelled as AR-V7, which are then degraded and / or otherwise inhibited by the compounds as described herein.
Owner:DBD THERAPEUTICS LLC

KRAS G12D proteolysis targeting chimera

Provided herein are KRAS G12D proteolysis targeting chimeras (PROTACs), compositions comprising the KRAS G12D PROTACs, and methods of making and using the KRAS G12D PROTACs, for example, to promote degradation of KRAS G12D and / or to treat cancers associated with KRAS G12D. KRAS G12D PROTAC has the structural formula: [KRAS G12Di]-L '-[Deron], or a pharmaceutically acceptable salt thereof, where KRAS G12Di is a KRAS G12D binding moiety, L' is a linker, and Deron is a selebron binding moiety. Preferably the compound is a compound of formula (VII). # imgabs0 #
Owner:PAQ THERAPEUTICS INC

Androgen receptor protacs

Certain Androgen receptor PROTAC (PROteolysis TArgeting Chimera) compounds contain a series of 2,4-dioxotetrahydropyrimidinyl derivatives that bind cereblon. The PROTAC compounds may be viewed as being comprised of an androgen receptor binding moieties, a linker and a cereblon binding moiety or degron. Medical uses of these PROTAC compounds are also disclosed.
Owner:GLAXOSMITHKLINE INTPROP DEV LTD

Oligonucleotide-based proteolysis targeting chimera

Compounds and pharmaceutical compositions useful to treat cancer (e.g., lymphoma), neurodegenerative diseases, and autoimmune disorders include (1) a first nucleic acid sequence capable of binding to a transcription factor, for example, a signal transducer and activator of transcription (STAT) factor, such as STAT3, (2) a second nucleic acid sequence capable of binding a Toll-like receptor protein, for example, a CpG oligodeoxynucleotide, and (3) a ubiquitin ligase binding compound capable of binding a ubiquitin ligase protein, for example, a compound that is capable of binding a cereblon protein, such as lenalidomide, pomalidomide, or thalidomide.
Owner:CITY OF HOPE

Synthesis and in vitro characterization of proteolysis targeting chimeras (protacs) for degradation of DNA methyltransferase 1 (DNMT1)

PCT designated stage expiredWO2025006902A3Organic chemistryPharmaceutical non-active ingredientsDiseaseCell Proliferation Process
Disclosed are bifunctional compounds (degraders) comprising a [Targeting ligand]-[Linker]-[Degron] adduct, the targeting ligand comprising a substituted pyridine compound, the bifunctional compounds targeting the epigenetic writer protein deoxyribonucleic acid methyltransferase 1, which is responsible for the maintenance of DNA methylation during cell proliferation, for degradation. Also disclosed are pharmaceutical compositions containing the compounds and methods of using the compounds to treat diseases and disorders characterized or mediated by aberrant DNMT1 activity.
Owner:DANA FARBER CANCER INSTITUTE INC